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Type 1 pilus directs bladder epithelial binding and invasion by uropathogenic Escherichia coli (UPEC) in the
initial stage of cystitis, but the bacterial determinants of postinvasion events in the pathogenesis of cystitis are
largely undetermined. We show here that the UPEC outer membrane protein A (OmpA), a monomeric, major,
integral protein component of the bacterial outer membrane, functions as a critical determinant of intracel-
lular virulence for UPEC, promoting persistent infection within bladder epithelium. Using a murine urinary
tract infection (UTI) model, we demonstrate that whereas deletion of the UPEC ompA gene did not disrupt
initial epithelial binding and invasion by UPEC, it did preclude completion of the intracellular bacterial
community (IBC) pathway, accompanied by diminishing bacterial loads in the bladder. This defect in epithelial
persistence of the ompA mutant was enhanced in competitive infections with wild-type UPEC. Microscopic
examinations revealed that the ompA mutant formed significantly fewer IBCs, and those that were initiated
were unable to progress past the early stages of maturation. These defects could be corrected by complemen-
tation of ompA. In addition, expression of ompA during wild-type UTI was sharply increased at time points
correlated with IBC development and the arrival of host immune effector cells. Our findings establish OmpA
as a key UPEC virulence factor that functions after epithelial invasion to facilitate IBC maturation and chronic
bacterial persistence.
The American patient population suffers each year from
approximately 11 million urinary tract infections (UTIs), which
are associated with an estimated $1.6 billion in clinical and
indirect economic costs (13, 15). This substantial morbidity is
exacerbated by the high frequency of recurrent infections de-
spite appropriate antimicrobial therapy. Many recurrences are
caused by organisms that are genotypically identical to the
initial infecting strain, suggesting that in addition to reinocu-
lation from a gastrointestinal source, recurrence might arise
after incomplete eradication of the organism from the bladder
(8). Uropathogenic Escherichia coli (UPEC) are the primary
etiology of UTIs, causing up to 90% of community-acquired
infections (45, 46). Persistence of UPEC within the urinary
tracts of experimentally infected mice has been associated with
their ability to invade superficial epithelial (umbrella) cells of
the bladder (34, 36), establishing a niche for host colonization
beyond the luminal surface to the intracellular compartment
and sheltering the pathogen from host defenses. Acute cystitis
is characterized by the development of intracellular bacterial
communities (IBCs) in both mice and humans (3, 47). The
IBCs represent clonal expansion of invaded bacteria proceed-
ing through a complex maturation cycle (24) that facilitates the
subsequent development of quiescent reservoirs or nests of
UPEC within Lamp1-positive intracellular vesicles (40). These
long-term resident bacteria are sequestered from antibiotic
therapy and remain apparently undetected by host immune
mechanisms (37).
While type 1 pili and flagella are critical and contributing
factors, respectively (16, 18, 53), for the early events of binding
and invasion, additional factors that promote the intracellular
phenotypes of UPEC are largely unidentified. We recently
demonstrated that the periplasmic chaperone SurA is required
for both invasion and intracellular maturation of UPEC (27).
This chaperone, conserved across numerous gram-negative
bacteria, facilitates transit of nascent polypeptides destined for
insertion into the outer membrane (OM) as -barrel porins
(11, 31). SurA deletion abrogates production of the type 1 pilus
usher FimD, thus precluding expression of type 1 pili and
epithelial colonization. However, SurA-dependent proteins
also contribute to postinvasion phenotypes of UPEC (19, 25).
More recently, deletion of the hfq gene (encoding an RNA
chaperone) was shown to impair the ability of UPEC to form
IBCs, perhaps through downstream effects on membrane in-
tegrity (30). Further, it is logical to surmise that the extracel-
lular domains of OM proteins might mediate pathogenesis by
participating in interactions with the host and potentially with
other bacteria in a community. Therefore, we sought to specify
SurA-dependent OM proteins that contribute to the postinva-
sion phenotypes of UPEC during cystitis, namely, IBC matu-
ration and intraepithelial persistence.
In the present study, we explored the pathogenic role of
outer membrane protein A (OmpA), a SurA-dependent, major
protein component of the E. coli OM that assumes a -barrel
conformation with eight transmembrane segments and four
extracellular loops (4). Multiple cellular functions have been
proposed for OmpA, including maintaining cell structural in-
tegrity, serving as a phage and colicin receptor, and mediating
F-factor-dependent conjugation (29). Although its role as a
porin is debated (5, 7), some data suggest that OmpA may
form nonspecific channels for diffusion of solutes. With regard
to bacterial virulence, OmpA is necessary for successful infec-
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tion by E. coli K-1, the leading gram-negative cause of neonatal
septicemia and meningitis (51). E. coli K-1 ompA mutants are
significantly less serum resistant (42, 52) and show decreased
capacity to invade cultured human brain microvascular endo-
thelial cells, which model the blood-brain barrier (41, 43).
Other authors have speculated that OmpA represents a patho-
gen-associated molecular pattern that interacts with antigen-
presenting cells (20–22). In UPEC the pathogenic function of
OmpA has yet to be elucidated, although it was one of several
OM proteins whose expression was augmented during in vitro
growth of UPEC in urine (1). We demonstrate here that
OmpA provides a pathogenic advantage to UPEC during es-
tablishment of its intracellular niche and promotes persistence
of UPEC within the bladder following acute cystitis.
MATERIALS AND METHODS
Bacterial strains and media. E. coli strains were cultured overnight at 37°C in
Luria-Bertani (LB) broth (Difco/Becton Dickinson, Franklin Lakes, NJ) under
static conditions to promote surface expression of type 1 pili. Where indicated,
chloramphenicol was added at 20 g/ml or ampicillin was added at 100 g/ml.
UPEC strain UTI89 was isolated from a patient with active cystitis. UTI89
ompA::cat was created by linear transformation of UTI89/pKM208 (38) with
a fragment amplified from template plasmid pKD3 (12) using the primers
5-ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGTGTAGG
CTGGAGCTGCTTC-3 (forward) and 5-TTAAGCCTGCGGCTGAGTTA
CAACGTCTTTGATGCCCATATGA ATATCCTCCTTAG-3 (reverse; In-
tegrated DNA Technologies, Coralville, IA). The deletion was verified by direct
sequencing, and the absence of OmpA expression by UTI89 ompA::cat was
confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis
of the total membranes. Of note, ompA is independently transcribed in UTI89
(9) and other sequenced strains of E. coli, so polar effects were excluded. For
complementation experiments, a low-copy-number plasmid (pKW5) encoding
ompA under its native promoter was constructed. The ompA gene and upstream
region were amplified by high-fidelity PCR using primers 5-CGTGTCTAGAT
TTCCTTGCGGAGGCTTGTCTGAAGCGGTTTC-3 (forward) and 5-ACCC
AAGCTTAACTTAAGCCTGCGGCTGAGTTACAACGTC-3 (reverse). This
fragment was digested with HindIII and XbaI and then ligated into pACYC184
(Cmr Tetr) that had been similarly digested, leaving expression of the marker
under the upstream influence of ompA’s native promoter. Transformed clones of
E. coli Top10 (Invitrogen, Carlsbad, CA) were selected on tetracycline plates and
tested by colony PCR, the construct was confirmed by direct sequencing, and
expression was confirmed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis analysis of the total membranes. Prior to mouse inoculations, the com-
plemented ompA/pKW5 strain was grown in only 5 g of tetracycline/ml to
keep the plasmid copy number low, since ompA overexpression at high levels was
detrimental to growth in vitro. UTI89 fimH, which lacks the gene encoding the
type 1 pilus tip adhesin, was kindly provided by K. Wright (53). To facilitate
visualization by confocal microscopy, UTI89 and derivatives were transformed
with pcomGFP (10).
Electron microscopy and hemagglutination assays. For immunogold electron
microscopy, washed bacteria were adsorbed to Formvar/carbon-coated grids,
incubated sequentially with primary rabbit antiserum raised against the ad-
hesin domain of the type 1 pilus adhesin FimH (denoted FimHA) and gold-
conjugated antirabbit immunoglobulin G, and washed twice with distilled
water before staining with 1% aqueous uranyl acetate. Samples were viewed
on a JEOL 1200EX transmission electron microscope (JEOL USA, Peabody,
MA). To assess in vitro function of type 1 pili, hemagglutination of guinea pig
erythrocytes (Colorado Serum Co., Denver, CO) was assayed as described
previously (32).
Ex vivo gentamicin protection assay and murine cystitis. A well-described
model of murine cystitis was used (36). All animal procedures were approved by
the Animal Studies Committee at Washington University. Briefly, overnight
static LB broth cultures were harvested by centrifugation, washed, resuspended,
and diluted to the final inoculum in phosphate-buffered saline (PBS), guided by
an optical density at 600 nm. Eight-week-old female C3H/HeN mice (Harlan,
Indianapolis, IN) were transurethrally infected with a 50-l inoculum of 107
bacteria. For ex vivo gentamicin protection (invasion) assays, bladders were
harvested at the indicated times postinfection, splayed aseptically, and then
washed with PBS to recover the luminal bacteria. Bladders processed for titers
were rocked gently in PBS containing gentamicin (100 g/ml) for 1 h at 37°C to
kill the remaining extracellular bacteria, homogenized in PBS, and plated to LB
agar to recover intracellular bacteria. For time course infections, bladders were
homogenized at the indicated times postinfection in sterile PBS with 0.1% Triton
X-100, serially diluted, and plated onto LB agar to enumerate the CFU. For
competitive infections, equal amounts of UTI89 and UTI89 ompA::cat were
mixed immediately prior to inoculation to a final density of 107 bacteria in a
50-l inoculum, and harvested bladder homogenates were plated on LB agar
with or without chloramphenicol. For complementation experiments, homoge-
nates were plated to LB agar with or without tetracycline to ensure reporting of
data from mice in which the complementing plasmid had been retained. Exper-
iments were repeated at least three times, and aggregate CFU data from these
independent experiments were reported.
LacZ staining and fluorescent confocal microscopy. For lacZ staining, groups
of three to four mice were infected with indicated strains; bladders were
stretched, fixed for 30 min in 10% neutral buffered formalin, washed with lacZ
wash buffer (PBS with 0.01 M MgCl2, 0.01% sodium deoxycholate, and 0.02%
Igepal CA-640), incubated in lacZ stain (lacZ wash buffer with 1 mg of X-Gal
[5-bromo-4-chloro-3-indolyl--D-galactopyranoside]/ml, 5 mM potassium ferro-
cyanide, and 5 mM potassium ferricyanide) for 16 h, washed three times in PBS,
and photographed by stereomicroscopy in whole mount for enumeration of the
spots representing IBCs (27). Bladders were then embedded in paraffin and, as
needed, sections were deparaffinized and stained with hematoxylin and eosin for
light microscopy. For confocal microscopy, freshly harvested bladders from ex-
perimental groups of three to four mice were stretched under PBS, fixed with 3%
paraformaldehyde in PBS for 1 h, and stained briefly with SYTO 61 red fluo-
rescent nucleic acid stain (Molecular Probes, Carlsbad, CA) to visualize any
bacteria that had lost the green fluorescent protein-containing plasmid. Bladders
were then washed with PBS, mounted on glass slides with ProLong Gold antifade
reagent (Molecular Probes), and viewed by using an LSM510 Meta laser scan-
ning confocal microscope (Carl Zeiss, Inc., Thornwood, NY). Aggregate data
from three independent experiments were reported.
RNA isolation and real-time PCR. Bladders infected with UTI89 as described
above were harvested at the indicated time points, homogenized, and stored at
80°C in RNA Protect reagent (Qiagen, Valencia, CA) according to the man-
ufacturer’s instructions. For the calibrator control sample, a portion of the
unused inoculum (109 CFU/ml in sterile PBS) was similarly treated and stored at
80°C. For analysis, stored bladder homogenates were thawed and centrifuged
(16,000  g for 5 min); supernatants were discarded, and the pellets (from five
animals per group) were pooled and resuspended in lysis buffer (RLT; Qiagen).
Samples were further homogenized with a FastPrep FP120 reciprocal shaking
device and a commercially available extraction reagent, lysing matrix B (MP
Biomedicals, Solon, OH). For analysis of ompA transcript levels in luminal and
intracellular compartments, a gentamicin protection approach was used as de-
scribed above. An aliquot of the luminal wash plus an aliquot of bladder ho-
mogenate after gentamicin treatment were stored at 80°C in RNA Protect
reagent until subsequent RNA extraction and analysis.
Total RNA was extracted by silica column purification using an RNeasy mini-
kit (Qiagen) according to the manufacturer’s instructions. Contaminating chro-
mosomal DNA was removed by on-column DNase (Qiagen) and, when neces-
sary, a second DNase treatment (Invitrogen). The absence of DNA was
confirmed by PCR, and the quality and quantity of RNA were determined by
spectrophotometry and agarose gel electrophoresis. First-strand cDNA was syn-
thesized by using Superscript II reverse transcriptase (Invitrogen) and random
primers. Real-time PCR was performed in an ABI 7500 Fast thermal cycler using
Power SYBR green PCR master mix (both from Applied Biosystems, Foster
City, CA) and primers designed to amplify E. coli ompA (forward, 5-GGGTG
TTTCCTACCGTTTCG-3; reverse 5-TGGAGCCGGAGCAACTACTG-3)
and the rRNA gene rrsA (forward, 5-CCAGGGCTACACACGTGCTA-3; re-
verse 5-TCTCGCGAGGTCGCTTCT-3), chosen as the endogenous control
gene because of invariable expression in a variety of conditions and the efficiency
of the PCR with the reagents and conditions used in these studies (J. Loughman,
unpublished data). Fold changes in message abundance (of triplicate assays)
were determined by using the CT method (33) by normalizing cycle threshold
(CT) values to each gene’s CT value obtained from baseline expression in the
starting inoculum.
Statistical analysis. Statistical analysis of numerical data was performed by
using the Mann-Whitney U test (two-tailed) or Wilcoxon test within Prism
software (GraphPad, La Jolla, CA). A P value of 0.05 was used as the threshold
of significance.
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OmpA of UPEC is not required for type 1 pilus-dependent
binding and invasion of bladder epithelium. Expression of
functional type 1 pili confers upon UPEC the ability to bind
mannosylated uroplakin proteins on the luminal surface, per-
mitting invasion of the mammalian bladder epithelium (34,
49). Although SurA is necessary for these type 1 pilus-depen-
dent functions, our objective was to identify SurA-dependent
proteins that contribute (independent of type 1 pili) to the
postinvasion biology of cystitis. Therefore, we first determined
whether deletion of ompA in the cystitis-derived UPEC strain
UTI89 affects the presentation or function of type 1 pili.
Growth of UTI89 in LB broth and resistance to novobiocin (a
measure of membrane integrity [26]) were unchanged by ompA
deletion (data not shown). Immunogold electron microscopic
images of wild-type and OmpA-deficient UTI89 displayed nor-
mal and equivalent numbers of pili, which labeled with anti-
FimHA antibody (Fig. 1A and B). The ompA mutant aggluti-
nated guinea pig erythrocytes as effectively as wild-type UTI89
(Fig. 1C), and agglutination by both strains was inhibited by
addition of 2% -D-mannopyranoside (data not shown). To
assess type 1 pilus function in mammalian infection, we per-
formed an ex vivo gentamicin protection assay in female C3H/
HeN mice. We recovered comparable levels of both luminal
and intracellular bacteria from bladders 1 h after infection with
ompA mutant or wild-type UTI89 (Fig. 1D). Taken together,
these data indicate that lack of OmpA in UPEC does not affect
type 1 pilus assembly, presentation, or function and that epi-
thelial binding and invasion are unaffected by UPEC ompA
deletion in the murine model of cystitis.
OmpA promotes acute and persistent UTI. UPEC attributes
that specifically contribute to intracellular pathogenesis, sub-
sequent to initial epithelial colonization, have yet to be dem-
onstrated. To determine whether OmpA has a role in uro-
pathogenesis, bladder bacterial loads of the ompA mutant
relative to wild-type UTI89 were evaluated along a time course
of murine cystitis. Female C3H/HeN mice were transurethrally
inoculated with 107 CFU of wild-type or OmpA-deficient
UTI89, and bladders were harvested at multiple time points
(from 6 h to 2 weeks) for tissue CFU determination. Time
points were chosen to reflect distinct stages of IBC develop-
ment and chronic persistence (2, 24, 40). Up to 24 h postin-
fection, CFU recovered from bladders infected with wild-type
UTI89 or its ompA mutant were similar (Fig. 2). In contrast,
there was a trend toward lower CFU in ompA::cat strain-
infected bladders at 48 h (an interval associated with late
fluxing bacteria and second-round IBC development) and a
statistically significant decrease in CFU in ompA::cat strain-
infected bladders at 1 and 2 weeks (P 	 0.001). At this final
time point, concomitant with reservoir formation, many of the
ompA::cat strain-infected bladders were found to be sterile
(Fig. 2). Compared to wild-type infection, CFU recovered
from the kidneys after 1 week were also sharply attenuated by
ompA deletion (data not shown). Mice infected with the com-
plemented ompA/pKW5 strain demonstrated restoration of
wild-type levels of recoverable tetracycline-resistant bladder
CFU at these time points (Fig. 2). During competitive infec-
tion with both the mutant and wild-type strains, late-stage
bladder CFU defects were amplified, with ompA mutant CFU
FIG. 1. Type 1 pilus expression and function in the UPEC ompA
mutant. Immunogold electron microscopy demonstrates equivalent
pilus expression in wild-type UTI89 (A) and the ompA mutant (B).
(C) The hemagglutination of guinea pig erythrocytes by wild-type
(WT) and ompA mutant UTI89 is equivalent; the UTI89 fimH mutant
is included as a negative control. In ex vivo gentamicin protection
assays, CFU recovered 1 h after infection with either wild type or
ompA mutant UTI89 are equivalent in the luminal and intracellular
compartments (D). Scale bar for panels A and B, 200 nm.
FIG. 2. Bacterial loads in the bladders of C3H/HeN mice at the
indicated time points after infection with either wild-type UTI89 (f),
the ompA mutant (E), or the complemented ompA/pKW5 strain (u),
and the dashed line indicates the limit of detection (10 CFU/bladder).
Bacterial loads of the ompA mutant begin to fall at 48 h and are
significantly lower than the wild type at 1 week and 2 weeks postin-
fection (*, P 	 0.001), and this difference is complemented when
ompA is provided in trans.
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beginning to fall by 24 h and the mutant universally cleared by
2 weeks (P 	 0.015; Fig. 3). Recoverable wild-type CFU were
unaffected by coinfection with the ompA mutant (compare the
wild-type CFU values in Fig. 2 to those in Fig. 3). CFU defects
at the observed time points suggest that OmpA is important for
completion of the IBC pathway and for subsequent persistence
within the bladder.
OmpA is necessary for IBC maturation during acute UTI.
Development of IBCs is vital for UPEC’s early survival in the
face of the bladder’s mucosal and innate immune defenses and
is required for establishment of chronic infection (3, 24, 26).
To examine the morphological correlates of the observed CFU
defects of the ompA mutant, we assessed global IBC presen-
tation via LacZ staining of whole-mount bladders, which ex-
ploits the fact that UTI89 (like all E. coli strains) expresses
-galactosidase. At 6 h after infection of C3H/HeN mice, blad-
ders infected with UTI89 displayed a mean of 30 IBCs per
half-bladder, versus only 8 IBCs per half-bladder after infec-
tion with the ompA mutant (P 
 0.007; Fig. 4A). Complemen-
tation of the mutant with pKW5 restored IBC numbers to 32
per half-bladder (Fig. 4A). Bladder sections taken from mice
6 h after infection with UTI89 or the ompA mutant strain were
also viewed by light microscopy. At this early stage, the size
and appearance of the few visualized ompA mutant IBCs sug-
gested a modest defect in development compared to wild-type
IBCs (Fig. 4B and C).
To assess the potential of the UPEC ompA mutant to com-
plete IBC maturation and proceed to later stages of the patho-
genic cascade of murine cystitis, we examined by fluorescent
confocal microscopy the bladders of C3H/HeN mice infected
with UTI89 or ompA::cat carrying gfp. Consistent with previous
results (24), wild-type UTI89 formed normal early IBCs by 6 h
(data not shown), and mature IBCs and many filamentous
forms by 16 h (Fig. 5A and B). In animals infected with OmpA-
deficient bacteria, we located no IBCs at 6 h by this technique
(data not shown). At 16 h rare, small intracellular collections
of ompA mutant were visualized, but these poorly formed
OmpA-deficient IBCs contained fewer bacteria and appeared
smaller in dimension than wild-type IBCs (Fig. 5C). Similarly,
few examples of stunted filamentous forms were seen after
ompA::cat strain infection (Fig. 5D). These defects were re-
stored by complementation with pKW5 (Fig. 5E and F). Al-
though bladders infected with wild-type UTI89 also demon-
strated IBCs at 24 h postinfection, mice infected with the
mutant lacked persisting IBCs at this time point, also restored
by complementation with pKW5 (data not shown). These find-
ings indicate that OmpA is necessary for UPEC to form ma-
ture IBCs, expand within their intracellular niche, and develop
filaments that initiate subsequent rounds of invasion and IBC
formation (24, 27).
Expression of ompA is temporally regulated during murine
cystitis. Loss of OmpA leads to pathogenic defects that are
evident at discrete stages of pathogenesis, namely, morpholog-
ical IBC abnormalities in the acute phase and subsequent
defects in persistence. We tested the hypothesis that ompA
expression would be regulated in correlation with the various
stages of pathogenesis by measuring transcript levels in vivo
with reverse transcription-PCR (RT-PCR). After standard in-
fection of C3H/HeN mice with wild-type UTI89, bladders were
harvested at time points from 6 h to 2 weeks, and the abun-
dance of ompA transcript was determined and normalized to
expression of the endogenous control gene rrsA. The data were
expressed as the fold change in transcript abundance com-
pared to that in the initial infecting inoculum. Expression of
ompA was upregulated (20- to 35-fold) at 16 to 24 h, returning
nearer to baseline at subsequent time points (Fig. 6A). To
determine whether ompA expression was elevated specifically
by bacteria within the extracellular and/or intracellular com-
partments of the bladder, RT-PCR was performed on luminal
washes and gentamicin-treated bladder homogenates from
mice 16 and 48 h after infection with UTI89. Analysis at 16 h
demonstrated upregulation of ompA in both fractions (Fig.
6B), with higher expression in the luminal compartment. At
FIG. 3. CFU recovered at the indicated time points after compet-
itive coinfection of C3H/HeN mice with both wild-type and ompA
mutant UTI89. The competitive fitness of the ompA mutant is sharply
attenuated as early as 24 h (*, P 
 0.002 to 0.015).
FIG. 4. Early IBC formation in C3H/HeN mice. (A) The numbers
of IBCs detected at 6 h by LacZ staining are significantly lower after
infection with the ompA mutant, compared to wild-type UTI89 (P 

0.007) or the complemented ompA/pKW5 strain (P 
 0.04). By light
microscopy, wild-type early IBCs are readily detected in hematoxylin-
and-eosin-stained bladder sections (B); modest intracellular replica-
tion was evident in occasional ompA mutant IBCs (C).
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48 h, expression levels remained elevated over the baseline but
more comparable between extracellular and intracellular com-
partments. These data suggest that ompA is upregulated by
intracellular bacteria, supporting IBC formation and matura-
tion, but also in extracellular bacteria, which are predomi-
nantly exposed to host innate immune pressures.
DISCUSSION
The present study demonstrates the SurA-dependent OmpA
as a critical player in the pathogenesis of UPEC, necessary for
progression of cystitis beyond the early stage of IBC formation
and essential for the intraepithelial persistence that is thought
to underlie recurrence of UTI (35, 39, 40). The loss of OmpA
in UPEC had no discernible effect on the assembly or function
of surface-expressed type 1 pili, as demonstrated by electron
microscopy and in vitro hemagglutination. Further, there was
no effect of ompA lack on bladder epithelial binding and inva-
sion in vivo, indicating that OmpA also does not augment or
facilitate these type 1 pilus-mediated functions. In contrast,
OmpA of E. coli K-1 was found to confer binding of cultured
human brain microvascular endothelial cells, a model of the
blood-brain barrier (44). In these same studies, however,
OmpA did not facilitate binding of E. coli K-1 to other endo-
thelial cell types, suggesting specific receptor expression by
human brain microvascular endothelial cells (41, 44). We con-
clude that the UPEC ompA mutant was able to accomplish key
early steps in the pathogenesis of cystitis, namely, luminal
colonization, epithelial invasion, and initial intracellular repli-
cation.
The relative equivalence of observed bladder bacterial loads
at early time points after wild-type and ompA mutant infec-
tions suggests only a modest effect on luminal and early intra-
cellular replication. However, bacterial loads of the ompA mu-
tant fell sharply at later time points, a difference even more
evident during competitive coinfections. Our microscopic in-
vestigations demonstrated that the UPEC ompA mutant could
indeed form initial intracellular collections but was incompe-
tent for progression past the early stage of IBC maturation;
these data indicate that successful epithelial invasion is insuf-
ficient to ensure completion of the IBC pathway. An additional
finding that supports the importance of OmpA during IBC
maturation was that ompA expression was upregulated by in-
tracellular bacteria at this stage. Interestingly, ompA was not
differentially regulated (compared to growth in LB broth) in
bacteria from sequential urine samples of CBA/J mice inocu-
lated repeatedly with another UPEC strain, CFT073 (isolated
from a patient with pyelonephritis) (17). However, in our
study, the infecting strain (a cystitis isolate) and method of
infection were distinct, and our data specifically measured in-
tracellular as well as extracellular bacterial expression of
ompA.
The observed failure of the ompA mutant to complete the
FIG. 5. Confocal microscopic examination of IBC maturation and
filamentation. Consistent with previous results, mature IBCs were
readily identified 16 h after wild-type UPEC infection (A), whereas a
rare, stunted intracellular collection was found at this time point after
infection with the ompA mutant (C). Similarly, robust filamentous
bacterial populations were evident 16 h after wild-type infection (B), in
contrast to the sparse filamentous forms seen after infection with the
ompA mutant (D). In mice infected with the complemented ompA/
pKW5 strain, the formation of mature IBCs (E) and filaments (F) was
restored. Scale bars, 10 m.
FIG. 6. RT-PCR analysis of ompA expression in bladder RNA ex-
tracts. (A) RT-PCR performed on whole-bladder extracts demon-
strates upregulation of ompA expression at 16 and 24 h, which subsides
to still-elevated levels at 48 h to 2 weeks after infection with UTI89.
(B) RNA isolated separately from the luminal and gentamicin-pro-
tected (intracellular) fractions reveals upregulation of ompA in both com-
partments at 16 and 48 h. The dashed line in each graph depicts the
baseline (inoculum) level of ompA expression, used for comparison.
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IBC maturation cycle could be interpreted in several ways.
First, cells containing early ompA mutant IBCs might be more
easily or rapidly exfoliated by the host, leading to a lack of
visible IBCs at later time points. However, we did not observe
increased exfoliation in ompA mutant-infected mice. Also,
such a stochastic explanation is unlikely because decreased
numbers of ompA IBCs are evident microscopically before
exfoliation occurs in these mice, and continued defects in in-
tracellular replication and filamentation are observed at later
time points. We also speculate that OmpA might be necessary
for coalescence of the IBC through interbacterial interactions
or might act as a porin for traversal of nutrients (7) or other
solutes to support optimal growth in the intracellular compart-
ment, but the specific role(s) of OmpA in this venue have yet
to be determined.
Later stages of the IBC pathway are tailored to subvert host
immune responses: intracellular bacteria are provided a sanc-
tuary from neutrophils (24), and filamentous bacteria transit-
ing the extracellular space between rounds of IBC formation
are resistant to polymorphonuclear leukocyte phagocytosis and
killing (26). Establishment of chronic residence within the
bladder requires bacteria to survive these extracellular periods
of exposure to host immune effectors. On this basis, we spec-
ulate that OmpA deficiency may hamper the organism’s resis-
tance to the action of neutrophils or other components of
innate and/or adaptive immunity. For example, several studies
have demonstrated the in vitro capacity of UPEC strains to
downregulate the secretion of proinflammatory cytokines by
cultured epithelial cells (6, 19, 28). In vitro epithelial cytokine
suppression requires SurA (19), implying that one or more
integral OM proteins are involved; indeed, OmpA of E. coli
K-1 inhibits proinflammatory cytokine production from iso-
lated monocytes (48). Alternatively, OmpA of UPEC might
protect the organism from antimicrobial peptides secreted by
polymorphonuclear leukocytes, as demonstrated in vitro for
OmpA of E. coli K-1 (14). Such a need for OmpA during these
extracellular phases of cystitis is also evidenced by upregula-
tion of ompA in luminal bacteria, which are exposed as innate
responses are being mustered. Our ongoing studies aim to
further specify the mechanism(s) of OmpA interactions with
the host. Whatever the mechanism, the effect of ompA deletion
is specific, rather than reflecting more generally the lack of a
major OM protein, as ompC deletion does not recapitulate the
ompA phenotypes (S. Chen, unpublished data).
OmpA has not previously been demonstrated to contribute
to urovirulence, although it was identified as an antigen ex-
pressed during cystitis (17) and during bacterial growth in
urine (1). Strong immunoreactivity against an array of OM
proteins, including OmpA, was shown when OM extracts
from the pyelonephritis strain CFT073 were separated by two-
dimensional gel electrophoresis and probed with sera from
mice chronically infected with the strain (17). The ability of
OmpA to stimulate mammalian adaptive responses also makes
it an attractive vaccine candidate (21, 23, 50). Our results
support this potential exploitation of OmpA; priming the
adaptive immune system with the capacity to respond to this
important determinant of later-stage pathogenic phenotypes
might offer benefit in preventing the establishment of chronic
bacterial reservoirs, thereby precluding subsequent recur-
rences of UTI.
ACKNOWLEDGMENTS
This study was supported by Public Health Service grants DK067894
and DK076556 (to D.A.H.); the Washington University Child Health
Research Center (HD01487); and the Edward Mallinckrodt, Jr., Foun-
dation of St. Louis, MO. T.F.N. was supported by a Ford Foundation
Diversity Fellowship administered by the National Academies.
We thank J. Loughman for technical assistance and P. Tarr and M.
Caparon for critical review of the manuscript.
REFERENCES
1. Alteri, C. J., and H. L. Mobley. 2007. Quantitative profile of the uropatho-
genic Escherichia coli outer membrane proteome during growth in human
urine. Infect. Immun. 75:2679–2688.
2. Anderson, G. G., K. W. Dodson, T. M. Hooton, and S. J. Hultgren. 2004.
Intracellular bacterial communities of uropathogenic Escherichia coli in uri-
nary tract pathogenesis. Trends Microbiol. 12:424–430.
3. Anderson, G. G., J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser, and S. J.
Hultgren. 2003. Intracellular bacterial biofilm-like pods in urinary tract in-
fections. Science 301:105–107.
4. Arora, A., F. Abildgaard, J. H. Bushweller, and L. K. Tamm. 2001. Structure
of outer membrane protein A transmembrane domain by NMR spectros-
copy. Nat. Struct. Biol. 8:334–338.
5. Arora, A., D. Rinehart, G. Szabo, and L. K. Tamm. 2000. Refolded outer
membrane protein A of Escherichia coli forms ion channels with two con-
ductance states in planar lipid bilayers. J. Biol. Chem. 275:1594–1600.
6. Billips, B. K., A. J. Schaeffer, and D. J. Klumpp. 2008. Molecular basis of
uropathogenic Escherichia coli evasion of the innate immune response in the
bladder. Infect. Immun. 76:3891–3900.
7. Bond, P. J., J. D. Faraldo-Gomez, and M. S. P. Sansom. 2002. OmpA: a pore
or not a pore? Simulation and modeling studies. Biophys. J. 83:763–775.
8. Brauner, A., B. Kaijser, and I. Kuhn. 1994. Recurrent Escherichia coli
bacteraemia: clinical characteristics and bacterial properties. J. Infect. 28:
49–57.
9. Chen, S. L., C. S. Hung, J. Xu, C. S. Reigstad, V. Magrini, A. Sabo, D.
Blasiar, T. Bieri, R. R. Meyer, P. Ozersky, J. R. Armstrong, R. S. Fulton, J. P.
Latreille, J. Spieth, T. M. Hooton, E. R. Mardis, S. J. Hultgren, and J. I.
Gordon. 2006. Identification of genes subject to positive selection in uro-
pathogenic strains of Escherichia coli: a comparative genomics approach.
Proc. Natl. Acad. Sci. USA 103:5977–5982.
10. Cormack, B. P., R. H. Valdivia, and S. Falkow. 1996. FACS-optimized
mutants of the green fluorescent protein. Gene 173:33–38.
11. Danese, P. N., and T. J. Silhavy. 1998. Targeting and assembly of periplasmic
and outer-membrane proteins in Escherichia coli. Annu. Rev. Genet. 32:59–94.
12. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromo-
somal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad.
Sci. USA 97:6640–6645.
13. Foxman, B. 2002. Epidemiology of urinary tract infections: incidence, mor-
bidity, and economic costs. Am. J. Med. 113:5S–13S.
14. Fu, H., A. A. Belaaouaj, C. Dahlgren, and J. Bylund. 2003. Outer membrane
protein A deficient Escherichia coli activates neutrophils to produce super-
oxide and shows increased susceptibility to antibacterial peptides. Microbes
Infect. 5:781–788.
15. Griebling, T. L. 2007. Urinary tract infections in women, p. 587–620. In M. S.
Litwin and C. S. Saigal (ed.), Urologic diseases in America. U.S. Govern-
ment Printing Office, Washington, DC.
16. Gunther, I. N., J. A. Snyder, V. Lockatell, I. Blomfield, D. E. Johnson, and
H. L. Mobley. 2002. Assessment of virulence of uropathogenic Escherichia
coli type 1 fimbrial mutants in which the invertible element is phase-locked
on or off. Infect. Immun. 70:3344–3354.
17. Hagan, E. C., and H. L. Mobley. 2007. Uropathogenic Escherichia coli outer
membrane antigens expressed during urinary tract infection. Infect. Immun.
75:3941–3949.
18. Hultgren, S. J., T. N. Porter, A. J. Schaeffer, and J. L. Duncan. 1985. Role
of type 1 pili and effects of phase variation on lower urinary tract infections
produced by Escherichia coli. Infect. Immun. 50:370–377.
19. Hunstad, D. A., S. S. Justice, C. S. Hung, S. R. Lauer, and S. J. Hultgren.
2005. Suppression of bladder epithelial cytokine responses by uropathogenic
Escherichia coli. Infect. Immun. 73:3999–4006.
20. Jeannin, P., B. Bottazzi, M. Sironi, A. Doni, M. Rusnati, M. Presta, V.
Maina, G. Magistrelli, J. F. Haeuw, G. Hoeffel, N. Thieblemont, N. Corvaia,
C. Garlanda, Y. Delneste, and A. Mantovani. 2005. Complexity and comple-
mentarity of outer membrane protein A recognition by cellular and humoral
innate immunity receptors. Immunity 22:551–560.
21. Jeannin, P., G. Magistrelli, L. Goetsch, J. F. Haeuw, N. Thieblemont, J. Y.
Bonnefoy, and Y. Delneste. 2002. Outer membrane protein A (OmpA): a
new pathogen-associated molecular pattern that interacts with antigen pre-
senting cells-impact on vaccine strategies. Vaccine 20(Suppl. 4):A23–A27.
22. Jeannin, P., G. Magistrelli, N. Herbault, L. Goetsch, S. Godefroy, P. Char-
bonnier, A. Gonzalez, and Y. Delneste. 2003. Outer membrane protein A
renders dendritic cells and macrophages responsive to CCL21 and triggers




arch 26, 2014 by W







dendritic cell migration to secondary lymphoid organs. Eur. J. Immunol.
33:326–333.
23. Jeannin, P., T. Renno, L. Goetsch, I. Miconnet, J. P. Aubry, Y. Delneste, N.
Herbault, T. Baussant, G. Magistrelli, C. Soulas, P. Romero, J. C. Cerottini,
and J. Y. Bonnefoy. 2000. OmpA targets dendritic cells, induces their mat-
uration and delivers antigen into the MHC class I presentation pathway. Nat.
Immunol. 1:502–509.
24. Justice, S. S., C. Hung, J. A. Theriot, D. A. Fletcher, G. G. Anderson, M. J.
Footer, and S. J. Hultgren. 2004. Differentiation and developmental path-
ways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc.
Natl. Acad. Sci. USA 101:1333–1338.
25. Justice, S. S., D. A. Hunstad, J. R. Harper, A. R. Duguay, J. S. Pinkner, J.
Bann, C. Frieden, T. J. Silhavy, and S. J. Hultgren. 2005. Periplasmic
peptidyl prolyl cis-trans isomerases are not essential for viability, but SurA is
required for pilus biogenesis in Escherichia coli. J. Bacteriol. 187:7680–7686.
26. Justice, S. S., D. A. Hunstad, P. C. Seed, and S. J. Hultgren. 2006. Filamen-
tation by Escherichia coli subverts innate defenses during urinary tract in-
fection. Proc. Natl. Acad. Sci. USA 103:19884–19889.
27. Justice, S. S., S. R. Lauer, S. J. Hultgren, and D. A. Hunstad. 2006. Matu-
ration of intracellular Escherichia coli communities requires SurA. Infect.
Immun. 74:4793–4800.
28. Klumpp, D. J., A. C. Weiser, S. Sengupta, S. G. Forrestal, R. A. Batler, and
A. J. Schaeffer. 2001. Uropathogenic Escherichia coli potentiates type 1
pilus-induced apoptosis by suppressing NF-B. Infect. Immun. 69:6689–
6695.
29. Koebnik, R. 1999. Structural and functional roles of the surface-exposed
loops of the beta-barrel membrane protein OmpA from Escherichia coli. J.
Bacteriol. 181:3688–3694.
30. Kulesus, R. R., K. Diaz-Perez, E. S. Slechta, D. S. Eto, and M. A. Mulvey.
2008. Impact of the RNA chaperone Hfq on the fitness and virulence po-
tential of uropathogenic Escherichia coli. Infect. Immun. 76:3019–3026.
31. Lazar, S. W., M. Almiron, A. Tormo, and R. Kolter. 1998. Role of the
Escherichia coli SurA protein in stationary-phase survival. J. Bacteriol. 180:
5704–5711.
32. Lazar, S. W., and R. Kolter. 1996. SurA assists the folding of Escherichia coli
outer membrane proteins. J. Bacteriol. 178:1770–1773.
33. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression
data using real-time quantitative PCR and the 2C(T) method. Methods
25:402–408.
34. Martinez, J. J., M. A. Mulvey, J. D. Schilling, J. S. Pinkner, and S. J.
Hultgren. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithe-
lial cells. EMBO J. 19:2803–2812.
35. Mulvey, M. A. 2002. Adhesion and entry of uropathogenic Escherichia coli.
Cell. Microbiol. 4:257–271.
36. Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks,
J. Heuser, and S. J. Hultgren. 1998. Induction and evasion of host defenses
by type 1-piliated uropathogenic Escherichia coli. Science 282:1494–1497.
37. Mulvey, M. A., J. D. Schilling, and S. J. Hultgren. 2001. Establishment of a
persistent Escherichia coli reservoir during the acute phase of a bladder
infection. Infect. Immun. 69:4572–4579.
38. Murphy, K. C., and K. G. Campellone. 2003. Lambda Red-mediated recom-
binogenic engineering of enterohemorrhagic and enteropathogenic Esche-
richia coli. BMC Mol. Biol. 4:11.
39. Mysorekar, I. U., and S. J. Hultgren. 2006. Mechanisms of uropathogenic
Escherichia coli persistence and eradication from the urinary tract. Proc.
Natl. Acad. Sci. USA 103:14170–14175.
40. Mysorekar, I. U., M. A. Mulvey, S. J. Hultgren, and J. I. Gordon. 2002.
Molecular regulation of urothelial renewal and host defenses during infec-
tion with uropathogenic Escherichia coli. J. Biol. Chem. 277:7412–7419.
41. Prasadarao, N. V. 2002. Identification of Escherichia coli outer membrane
protein A receptor on human brain microvascular endothelial cells. Infect.
Immun. 70:4556–4563.
42. Prasadarao, N. V., A. M. Blom, B. O. Villoutreix, and L. C. Linsangan. 2002.
A novel interaction of outer membrane protein A with C4b binding protein
mediates serum resistance of Escherichia coli K1. J. Immunol. 169:6352–
6360.
43. Prasadarao, N. V., P. K. Srivastava, R. S. Rudrabhatla, K. S. Kim, S. H.
Huang, and S. K. Sukumaran. 2003. Cloning and expression of the Esche-
richia coli K1 outer membrane protein A receptor, a gp96 homologue. Infect.
Immun. 71:1680–1688.
44. Prasadarao, N. V., C. A. Wass, J. N. Weiser, M. F. Stins, S. H. Huang, and
K. S. Kim. 1996. Outer membrane protein A of Escherichia coli contributes
to invasion of brain microvascular endothelial cells. Infect. Immun. 64:146–
153.
45. Ronald, A. 2003. The etiology of urinary tract infection: traditional and
emerging pathogens. Dis. Mon. 49:71–82.
46. Ronald, A., and E. Ludwig. 2001. Urinary tract infections in adults with
diabetes. Int. J. Antimicrob. Agents 17:287–292.
47. Rosen, D. A., T. M. Hooton, W. E. Stamm, P. A. Humphrey, and S. J.
Hultgren. 2007. Detection of intracellular bacterial communities in human
urinary tract infection. PLoS Med. 4:e329.
48. Selvaraj, S. K., and N. V. Prasadarao. 2005. Escherichia coli K1 inhibits
proinflammatory cytokine induction in monocytes by preventing NF-B ac-
tivation. J. Leukoc. Biol. 78:544–554.
49. Sun, T. T., H. Zhao, J. Provet, U. Aebi, and X. R. Wu. 1996. Formation of
asymmetric unit membrane during urothelial differentiation. Mol. Biol. Rep.
23:3–11.
50. Torres, A. G., Y. Li, C. B. Tutt, L. Xin, T. Eaves-Pyles, and L. Soong. 2006.
Outer membrane protein A of Escherichia coli O157:H7 stimulates dendritic
cell activation. Infect. Immun. 74:2676–2685.
51. Wang, Y., and K. S. Kim. 2002. Role of OmpA and IbeB in Escherichia coli
K1 invasion of brain microvascular endothelial cells in vitro and in vivo.
Pediatr. Res. 51:559–563.
52. Weiser, J. N., and E. C. Gotschlich. 1991. Outer membrane protein A
(OmpA) contributes to serum resistance and pathogenicity of Escherichia
coli K-1. Infect. Immun. 59:2252–2258.
53. Wright, K. J., P. C. Seed, and S. J. Hultgren. 2007. Development of intra-
cellular bacterial communities of uropathogenic Escherichia coli depends on
type 1 pili. Cell. Microbiol. 9:2230–2241.
Editor: V. J. DiRita




arch 26, 2014 by W
ashington University in St. Louis
http://iai.asm
.org/
D
ow
nloaded from
 
